Keywords
breast cancer, Na+/K+-ATPase, gene expression, abnormality, ATP1A1, ATP1A2
breast cancer, Na+/K+-ATPase, gene expression, abnormality, ATP1A1, ATP1A2
Breast cancer is one of the most common and deadly female solid tumors1. According to reports from Perou et al.2, further confirmed by other investigators3,4, breast cancer is a highly molecularly heterogeneous disease. The identification of molecular genetic abnormalities in breast cancer is important to improve the results of treatment and, for instance, to reveal new targets for specific therapies. Recent studies based on original retrospective analysis of digitalis use in breast cancer patients have demonstrated the anticancer effect of cardiac glycosides5 that directly inhibit Na+/K+-ATPase (NKA) activity. NKA signaling functions after interaction with cardiac glycosides were also shown6. It seems rational that expression of NKA might influence breast cancer prognosis.
NKA is a significant integral membrane protein. NKA’s main function is the creation and maintenance of electrochemical gradients for sodium and potassium ions in the living cell. These gradients have critical importance for control of cell volume, osmolarity and resting potential7,8. The minimal functional NKA consists of two associated alpha- and beta- subunits. The catalytic alpha-subunit is responsible for conversion of ATP energy to transport of Na+ and K+ across cell membranes and has ATP and cardiac glycosides binding sites. It may be present in human tissues in four different isoforms (α1, α2, α3, α4 – found only in testicles). The beta-subunit is responsible for delivery and insertion of alpha one in cell membranes and has three distinct isoforms in humans (β1, β2, β3)8–10. NKA subunits are variably expressed in different human tissues11. Changes in the relative expression between different isoforms are associated with a number of pathological processes including malignant transformation12,13. Both down- and up-regulation of alpha- and beta- subunits were shown in solid tumors of different origin14–19.
In the present study, we analyzed public breast cancer expression profiles made using Affymetrix Human Genome U133 Plus 2.0 Array (NCBI GEO database20, accession GSE65194) for the expression of alpha subunits of NKA. We found abnormalities in ATP1A1 (coding α1-subunit) and ATP1A2 (coding α2-subunit) expression (Table 1) in breast cancer samples relative to their expression in normal breast tissue. ATP1A1 was overexpressed approximately 1.5 times in all groups of breast cancer samples (p<0.05). Coincidently, ATP1A2 expression decreased by more than 2 times (p<0.05). There were no differences observed in the expression of ATP1A3 (coding α3-subunit).
Preanalytical procedures consisted of a robust multichip analysis (RMA) algorithm21, including background correction, probe set signal integration, and quantile normalization. For this purpose, we used Expression Console 1.4 software (Affymetrix, Inc. USA). We utilized Transcriptome Analysis Console 3.0 software (Affymetrix, Inc. USA) to analyze the obtained CHP files and to detect differentially expressed genes using one-way between subjects ANOVA. Array data for 41 triple negative samples (TNBC group), 30 Her2-positive (Her2 group), 30 Luminal B (Lum B group), 29 Luminal A (Lum A group) breast cancer samples and 11 normal breast tissue samples were investigated.
Using a public microarray dataset we found abnormalities in the expression of ATP1A1 and ATP1A2 in breast cancer samples. This may correlate with digitalis anticancer activity, but requires additional research. We expect that our research could help to improve the understanding of predictive and prognostic features of breast cancer.
Raw data for Table 1 are available at:
https://www.ncbi.nlm.nih.gov/geo/download/?acc=GSE65194&format=file22.
Expression Console 1.4 software and Transcriptome Analysis Console 3.0 software (Affymetrix, Inc. USA) are available after free customer registration at:
http://www.affymetrix.com/support/technical/software_downloads.affx.
AB, FM and MD conceptualized the study, collected data and performed data analysis. All authors were involved in the writing and revision of the draft manuscript and have agreed to the final content.
This work was supported by The Ministry of Education and Science of Russian Federation (unique identifier of applied research: RFMEFI60414X0070).
Views | Downloads | |
---|---|---|
F1000Research | - | - |
PubMed Central
Data from PMC are received and updated monthly.
|
- | - |
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
Yes
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
Yes
Competing Interests: No competing interests were disclosed.
Competing Interests: No competing interests were disclosed.
Alongside their report, reviewers assign a status to the article:
Invited Reviewers | ||
---|---|---|
1 | 2 | |
Version 1 05 Jan 17 |
read | read |
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Already registered? Sign in
The email address should be the one you originally registered with F1000.
You registered with F1000 via Google, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Google account password, please click here.
You registered with F1000 via Facebook, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Facebook account password, please click here.
If your email address is registered with us, we will email you instructions to reset your password.
If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance.
Comments on this article Comments (0)